Despite an FDA citation for a clinical trial site, Coherus said it still expects an approval for Junshi-partnered PD-1 inhibitor this year. (Photo by Sarah Silbiger/Getty Images) The road to an FDA ...
Amgen ads talking up its Neulasta on-body injection system caught the FDA’s attention—with the help of some “Bad Ad” tattlers. The FDA slapped Amgen with an untitled letter last week for banner ad ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta. The Food and Drug Administration (FDA) approved Udenyca Onbody, an injector ...
With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro. With a ...
In its second untitled letter of 2021, the US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) flagged issues with Amgen’s promotion of its biological product Neulasta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results